NASDAQ:MCRB - Seres Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $22.29
  • Forecasted Upside: 201.57 %
  • Number of Analysts: 8
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$7.39
▼ -0.56 (-7.04%)

This chart shows the closing price for MCRB by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Seres Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MCRB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MCRB

Analyst Price Target is $22.29
▲ +201.57% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Seres Therapeutics in the last 3 months. The average price target is $22.29, with a high forecast of $32.00 and a low forecast of $7.00. The average price target represents a 201.57% upside from the last price of $7.39.

This chart shows the closing price for MCRB for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 8 investment analysts is to buy stock in Seres Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/1/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/1/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/30/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/28/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/26/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/26/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/25/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 1 sell ratings
7/25/2021

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/23/2021Canaccord GenuityLower Price TargetBuy$42.00 ➝ $29.00Medium
7/23/2021Chardan CapitalLower Price TargetBuy$30.00 ➝ $16.00Medium
7/23/2021HC WainwrightLower Price TargetBuy$46.00 ➝ $25.00High
7/23/2021The Goldman Sachs GroupDowngradeNeutral ➝ Sell$24.00 ➝ $7.00High
7/22/2021OppenheimerLower Price TargetOutperform$36.00 ➝ $18.00High
7/22/2021Piper SandlerLower Price TargetOverweight$40.00 ➝ $32.00High
7/9/2021Chardan CapitalInitiated CoverageBuy$30.00Low
7/1/2021Chardan CapitalReiterated RatingBuyLow
5/5/2021HC WainwrightBoost Price TargetPositive ➝ Buy$41.00 ➝ $46.00Medium
3/5/2021Chardan CapitalUpgradeNeutral ➝ Buy$27.50 ➝ $30.00High
3/2/2021OppenheimerReiterated RatingBuy$38.00High
12/23/2020JMP SecuritiesInitiated CoverageMarket PerformN/A
11/23/2020Canaccord GenuityReiterated RatingBuyHigh
11/9/2020OppenheimerBoost Price TargetPositive ➝ Outperform$34.00 ➝ $38.00Low
11/9/2020Piper SandlerBoost Price TargetPositive ➝ Overweight$40.00 ➝ $49.00Medium
10/26/2020OppenheimerReiterated RatingOutperform$29.00 ➝ $34.00Low
9/21/2020Canaccord GenuityBoost Price TargetBuy$38.00 ➝ $42.00High
9/18/2020Chardan CapitalDowngradeBuy ➝ Neutral$32.50 ➝ $27.50Medium
9/13/2020OppenheimerReiterated RatingBuy$29.00High
8/18/2020Piper SandlerInitiated CoverageOverweight$40.00Medium
8/11/2020HC WainwrightBoost Price TargetBuy$8.00 ➝ $41.00High
8/11/2020Jefferies Financial GroupUpgradeHold ➝ Buy$4.00 ➝ $29.00High
8/10/2020Chardan CapitalBoost Price TargetBuy$12.50 ➝ $32.50High
8/10/2020Canaccord GenuityBoost Price TargetBuy$11.00 ➝ $38.00Medium
8/10/2020OppenheimerBoost Price TargetOutperform$7.00 ➝ $30.00Medium
7/28/2020OppenheimerReiterated RatingBuy$7.00High
6/25/2020Chardan CapitalReiterated RatingBuy ➝ Market Perform$12.50Medium
5/8/2020Canaccord GenuityReiterated RatingBuy$11.00High
3/31/2020OppenheimerLower Price TargetOutperform$8.00 ➝ $7.00High
3/23/2020HC WainwrightReiterated RatingBuy$8.00High
11/21/2019HC WainwrightReiterated RatingBuy$8.00Low
11/4/2019CowenReiterated RatingBuyHigh
9/19/2019Chardan CapitalReiterated RatingBuyLow
7/1/2019Jefferies Financial GroupLower Price TargetHold$6.00 ➝ $4.00Low
6/17/2019Chardan CapitalReiterated RatingBuyLow
5/7/2019Cantor FitzgeraldReiterated RatingBuyHigh
5/7/2019CowenReiterated RatingBuyHigh
5/3/2019HC WainwrightReiterated RatingBuy$8.00High
5/2/2019Chardan CapitalReiterated RatingBuy$15.00High
4/30/2019Jefferies Financial GroupInitiated CoverageHold ➝ Hold$7.00High
3/19/2019OppenheimerReiterated RatingBuyLow
2/22/2019HC WainwrightReiterated RatingBuyLow
2/8/2019CowenReiterated RatingBuyLow
11/23/2018Cantor FitzgeraldReiterated RatingOverweightHigh
11/9/2018OppenheimerSet Price TargetBuy$16.00High
11/8/2018Cantor FitzgeraldSet Price TargetBuy$15.00High
10/28/2018Chardan CapitalReiterated RatingBuyMedium
10/22/2018Chardan CapitalInitiated CoverageBuy ➝ Buy$15.00Low
8/3/2018Bank of AmericaDowngradeNeutral ➝ UnderperformHigh
10/13/2017CIBCInitiated CoverageOutperform ➝ Outperform$19.00N/A
10/12/2017OppenheimerInitiated CoverageOutperform$19.00N/A
10/12/2017CitigroupInitiated CoverageOutperform ➝ Positive$19.00N/A
10/6/2017Seaport Global SecuritiesReiterated RatingBuy$20.00N/A
10/2/2017CowenReiterated RatingBuyHigh
8/30/2017Cantor FitzgeraldReiterated RatingBuyLow
8/4/2017HC WainwrightReiterated RatingBuy ➝ Buy$15.00 ➝ $19.00High
8/3/2017Canaccord GenuitySet Price TargetBuy$20.00Low
6/12/2017Canaccord GenuitySet Price TargetBuy$20.00Low
5/19/2017CowenReiterated RatingBuyMedium
5/4/2017Cantor FitzgeraldSet Price TargetBuy$16.00High
5/4/2017Canaccord GenuitySet Price TargetBuy$20.00High
3/21/2017Cantor FitzgeraldReiterated RatingOverweightLow
3/20/2017(FBRC)Reiterated RatingOutperform$18.00Low
2/1/2017CowenReiterated RatingBuyN/A
2/1/2017(FBRC)Lower Price TargetOutperform$23.00 ➝ $18.00N/A
1/31/2017Cantor FitzgeraldSet Price TargetBuy$16.00N/A
1/31/2017Canaccord GenuityReiterated RatingBuy$20.00N/A
1/11/2017Cantor FitzgeraldSet Price TargetBuy$16.00N/A
12/16/2016Cantor FitzgeraldInitiated CoverageOverweight$16.00N/A
8/12/2016(FBRC)Lower Price TargetOutperform$43.00 ➝ $23.00N/A
8/11/2016SVB LeerinkReiterated RatingBuy$12.00N/A
8/1/2016Canaccord GenuityReiterated RatingBuy$20.00N/A
8/1/2016SVB LeerinkReiterated RatingOutperform$43.00 ➝ $12.00N/A
8/1/2016Bank of AmericaDowngradeBuy ➝ NeutralN/A
7/29/2016CowenReiterated RatingBuyN/A
7/29/2016HC WainwrightInitiated CoverageBuy$50.00N/A
(Data available from 7/25/2016 forward)
Seres Therapeutics logo
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). It is also developing SER-287 that is in Phase IIb clinical trial to treat ulcerative colitis; SER-401, which is in Phase Ib clinical trial for use with checkpoint inhibitors in patients with metastatic melanoma; and SER-301 that is in the Phase 1b clinical trial for the treatment of inflammatory bowel disease. In addition, the company engages in the development of SER-262 to treat an initial recurrence of CDI; and SER-155, a cultivated bacteria microbiome drug designed to prevent mortality due to gastrointestinal infections, bacteremia, and graft versus host diseases in immunocompromised patients receiving allogeneic hematopoietic stem cell transplantation and solid organ transplants. It has license and collaboration agreements with Nestec Ltd. and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $7.39
Low: $7.25
High: $8.06

50 Day Range

MA: $20.65
Low: $7.39
High: $24.36

52 Week Range

Now: $7.39
Low: $3.67
High: $38.50

Volume

11,057,023 shs

Average Volume

1,614,299 shs

Market Capitalization

$677.52 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.93

Frequently Asked Questions

What sell-side analysts currently cover shares of Seres Therapeutics?

The following Wall Street analysts have issued research reports on Seres Therapeutics in the last twelve months: Canaccord Genuity, Chardan Capital, HC Wainwright, Jefferies Financial Group Inc., JMP Securities, Oppenheimer Holdings Inc., Piper Sandler, The Goldman Sachs Group, Inc., and Zacks Investment Research.
View the latest analyst ratings for MCRB.

What is the current price target for Seres Therapeutics?

7 Wall Street analysts have set twelve-month price targets for Seres Therapeutics in the last year. Their average twelve-month price target is $22.29, suggesting a possible upside of 201.6%. Piper Sandler has the highest price target set, predicting MCRB will reach $32.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $7.00 for Seres Therapeutics in the next year.
View the latest price targets for MCRB.

What is the current consensus analyst rating for Seres Therapeutics?

Seres Therapeutics currently has 1 sell rating, 1 hold rating and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MCRB will outperform the market and that investors should add to their positions of Seres Therapeutics.
View the latest ratings for MCRB.

What other companies compete with Seres Therapeutics?

How do I contact Seres Therapeutics' investor relations team?

Seres Therapeutics' physical mailing address is 200 SIDNEY STREET - 4TH FLOOR, CAMBRIDGE MA, 02139. The biotechnology company's listed phone number is 617-945-9626 and its investor relations email address is [email protected] The official website for Seres Therapeutics is www.serestherapeutics.com.